文献速递艾滋病与性传播感染医院感染防控

九价HPV疫苗在实体器官移植受者及HIV感染者中的免疫原性与安全性

Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV).
PubMed 文献 · Clin Infect Dis · 2021-01-01

这项III期研究在100名HIV感染者和171名实体器官移植受者中接种九价HPV疫苗,评估第7个月时的血清阳转率。HIV感染者对全部HPV型别均实现血清阳转,而移植受者血清阳转率从HPV45的46%到HPV58的72%不等。疫苗在两组中均安全且耐受性良好。

要点

  • HIV感染者接种九价HPV疫苗后对全部9种型别均产生血清阳转。
  • 实体器官移植受者血清阳转率较低,范围为46%至72%。
  • 疫苗在两组人群中均安全,注射部位不良事件多为轻中度。

核心结论

  • 九价HPV疫苗在HIV感染者中免疫原性高,但在实体器官移植受者中免疫原性欠佳。
  • 疫苗在HIV感染者和实体器官移植受者中均安全且耐受性良好。

研究设计与样本

  • III期研究者发起的研究,纳入100名18-45岁HIV感染者和171名18-55岁实体器官移植受者。
  • 九价HPV疫苗于第1天、第2个月和第6个月接种。
  • 主要结局为第7个月时对九价HPV疫苗型别的血清阳转率,次要结局为几何平均滴度和不良事件频率。

主要发现

  • 所有HIV感染者对全部HPV型别均发生血清阳转。
  • 实体器官移植受者的血清阳转率范围为46%(HPV45)至72%(HPV58)。
  • HIV感染者的几何平均滴度范围为180至2985 mMU/mL,实体器官移植受者为17至170 mMU/mL,具体取决于HPV型别。
  • 62%的参与者发生注射部位不良事件,但大多为轻度或中度。
  • 未报告任何严重不良事件被认为与疫苗相关,研究期间无患者死亡。

临床怎么用

  • 对于HIV感染者,九价HPV疫苗可提供高免疫原性,支持接种。
  • 对于实体器官移植受者,接种后免疫原性欠佳,可能需要考虑额外接种策略或加强监测。
  • 疫苗在两组人群中安全性良好,可耐受。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The burden of human papillomavirus (HPV) in human immunodeficiency virus (HIV)-infected persons and solid organ transplant (SOT) recipients is high. Clinical trials on HPV vaccines in persons living with HIV and particularly in SOT recipients have been sparse to date, included low numbers of participants, and none of them assessed the 9-valent HPV (9vHPV) vaccine. We investigated the immunogenicity with respect to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 and the safety of the 9vHPV vaccine in persons living with HIV and recipients of a kidney, lung, or heart transplant. METHODS: This is a phase III investigator-initiated study in 100 persons living with HIV (age 18-45 years) and 171 SOT recipients (age 18-55 years). The 9vHPV vaccine was administered at day 1, month 2, and month 6. Primary outcome was seroconversion rates to the 9vHPV types at month 7. Secondary outcomes were geometric mean titers (GMTs) and frequency of adverse events (AEs). RESULTS: All HIV-infected participants seroconverted for all HPV types, but seroconversion ranged from 46% for HPV45 to 72% for HPV58 in SOT recipients. GMTs ranged from 180 to 2985 mMU/mL in HIV-positive participants and from 17 to 170 mMU/mL in SOT recipients, depending on the HPV type. Injection-site AEs occurred in 62% of participants but were mostly mild or moderate in intensity. None of the reported serious adverse events were deemed vaccine related. No patients died during the study. CONCLUSIONS: Immunogenicity of the 9vHPV vaccine is high in persons living with HIV but suboptimal in SOT recipients. The vaccine is safe and well tolerated in both groups.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Boey L, Curinckx A, Roelants M, et al. Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2021. PMID: 33373429. doi:10.1093/cid/ciaa1897

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。